Johnson, M. http://orcid.org/0000-0001-5195-3379
Johnels, J. Åsberg
Östlund, S.
Jakobsson, K.
Högstedt, J.
Larsson, P. Javid
Gillberg, C.
Billstedt, E.
Funding for this research was provided by:
Takeda Pharmaceuticals International
Stiftelserna Wilhelm och Martina Lundgrens
Stiftelsen Petter Silfverskiölds Minnesfond
Fredrik och Ingrid Thurings Stiftelse
University of Gothenburg
Article History
Received: 12 April 2023
Accepted: 11 December 2023
First Online: 27 January 2024
Declarations
:
: MJ has been engaged as a speaker/consultant by PCM Scientific, Evolan, Shire/Takeda, SFI Health and New Nordic for work unrelated to the present paper. All other authors report no conflicts of interest.
: The Gothenburg ethical committee approved the original 1-year trial (no. 897-13), and an amendment for the 2-year extension (LMA trial, no. 725-16). Written informed consent/assent was obtained from the children and both parents after the nature of the procedures had been fully explained. The Swedish Medical Products Agency was informed about the trial, and it was registered in ClinicalTrials.gov, identifier NCT03250013.